Skip to main content

Table 1 Patient and donor characteristics

From: Donor-specific anti-human leukocyte antigen antibodies were associated with primary graft failure after unmanipulated haploidentical blood and marrow transplantation: a prospective study with randomly assigned training and validation sets

 

All patients

Training group

Validation group

P value

Patient number

345

173

172

 

Median age (range), years

26 (2–58)

26 (4–58)

26 (2–58)

0.830

Median weight (range), kg

62 (13–113)

61 (18–113)

63 (13–110)

0.388

Male sex, n (%)

201 (58.3)

100 (57.8)

101 (58.7)

0.863

Diagnosis, n (%)

   

0.142

 AML

137 (39.7)

69 (39.9)

68 (39.5)

 

 ALL

116 (33.6)

49 (28.3)

67 (39.0)

 

 CML

19 (5.5)

10 (5.8)

9 (5.2)

 

 MDS

38 (11.0)

24 (13.9)

14 (8.1)

 

 Others

35 (10.1)

21 (12.1)

14 (8.1)

 

Disease status, SR/HR (n (%))

265 (76.8)/80 (23.2)

135 (78.0)/38 (22.0)

135 (78.0)/38 (22.0)

0.589

Conditioning regimen

    

 MA

345 (100 %)

173 (100 %)

172 (100 %)

 

No of HLA-A, B, DR mismatched

   

0.302

 0

2 (0.6 %)

1 (0.6 %)

1 (0.6 %)

 

 1

18 (5.2 %)

13 (7.5 %)

5 (2.9 %)

 

 2

74 (21.4 %)

34 (19.7)

40 (23.3 %)

 

 3

249 (72.2 %)

124 (71.1 %)

125 (72.2 %)

 

Donor-recipient sex match, n (%)

   

0.609

 Male-male

132 (38.3)

63 (36.4)

69 (40.1)

 

 Male-female

89 (25.8)

42 (24.3)

47 (27.3)

 

 Female-male

71 (20.6)

38 (22.0)

33 (19.2)

 

 Female-female

53 (15.4)

30 (17.3)

23 (13.4)

 

Donor-recipient relationship, n (%)

   

0.419

 Father-child

134 (38.8)

64 (37.0)

70 (40.7)

 

 Mother-child

45 (13.0)

28 (16.2)

17 (9.9)

 

 Sibling-sibling

103 (29.9)

53 (30.6)

50 (29.1)

 

 Child-parent

53 (15.4)

25 (14.5)

28 (16.3)

 

 Other

10 (2.9)

3 (1.7)

7 (4.1)

 

ABO matched, n (%)

   

0.345

 Matched

196 (56.8)

102 (59.2)

94 (54.7)

 

 Major mismatched

64 (18.6)

34 (19.7)

30 (17.4)

 

 Minor mismatched

18 (5.2)

10 (5.8)

8 (4.7)

 

 Bidirect mismatched

67 (19.4)

27 (15.6)

40 (23.3)

 

Cell compositions in allografts

    

 Infused nuclear cells 108/kg

8.34 (1.78–23.69)

8.32 (1.78–23.59)

8.40 (2.12–23.69)

0.321

 Infused CD34+ cells 106/kg

2.59 (0.39–16.82)

2.71 (0.39–14.47)

2.49 (0.58–16.82)

0.840

 Infused lymphocytes 108/kg

2.95 (0.16–9.49)

2.88 (0.16–9.49)

3.06 (0.68–7.34)

0.107

 Infused CD3+ cells 108/kg

2.00 (0.10–5.93)

2.00 (0.10–5.93)

1.99 (0.20–5.36)

0.575

 Infused CD4+ cells 108/kg

1.10 (0.10–3.94)

1.09 (0.10–3.33)

1.13 (0.19–3.94)

0.371

 Infused CD8+ cells 108/kg

0.70 (0.05–2.47)

0.69 (0.05–2.47)

0.72 (0.14–2.43)

0.452

 Infused CD14+ cells 108/kg

1.49 (0.05–4.90)

1.50 (0.33–4.90)

1.48 (0.05–6.13)

0.769

  1. Abbreviations: AML acute myeloid leukemia, ALL acute lymphoblastic leukemia, CML chronic myeloid leukemia, MDS myelodysplastic syndrome, HLA human leukocyte antigen, BM bone marrow